A subset of frontotemporal dementia cases are neuropathologically defined by tau-negative, TAR DNAbinding protein-43, and ubiquitin-positive inclusions in the brain and are associated with mutations in the progranulin gene (GRN). Deep sequencing of families exhibiting late-onset dementia revealed several novel variants in GRN. Because of the small size of these families and limited availability of samples, it was not possible to determine whether the variants segregated with the disease. Furthermore, none of these families had autopsy confirmation of diagnosis. We sought to determine if these novel GRN variants alter progranulin (PGRN) protein stability, PGRN secretion, and PGRN cleavage in cultured cells. All the novel GRN variants behave like PGRN wild-type protein, suggesting that these variants represent rare polymorphisms. However, it remains possible that these variants affect other aspects of PGRN function or represent risk factors for dementia when combined with other modifying genes.
Introduction
Frontotemporal dementia (FTD) is a late-onset neurodegenerative disease that is clinically characterized by disturbances in language, behavior, and personality (Cairns et al., 2007) . A subset of FTD cases, termed FTLD-U, are neuropathologically defined by taunegative, TAR , and ubiquitinpositive inclusions in the brain and are associated with mutations in the progranulin gene (GRN) (Baker et al., 2006; Cruts et al., 2006) . Progranulin (PGRN) is a 68-kDa glycoprotein. Glycosylation of PGRN produces high molecular weight proteins, the most common of which is an 88-kDa protein. PGRN is secreted from the cell as a full-length protein and converted into 6e25 kDa fragments, termed granulins (GRN), via proteolytic processing by elastase and other extracellular proteases. Most FTLD-Ueassociated GRN mutations cause premature termination of the coding sequence, resulting in nonsense-mediated decay; however, some missense variants have been described that cause FTLD-U by other mechanisms (Gass et al., 2012; Mukherjee et al., 2008; Wang et al., 2010) .
Deep sequencing efforts in 439 clinically diagnosed late-onset Alzheimer's disease (LOAD) families, without autopsy confirmation of diagnosis, have identified rare variants in GRN in several families (Cruchaga et al., 2012) . Because of the rarity of these variants and the small families and/or incomplete pedigree data, determining pathogenicity of these rare GRN variants is challenging.
To further investigate the impact of these variants, we tested whether they behave like known pathogenic FTLD-Ueassociated GRN mutations in vitro. All novel PGRN variants behaved like PGRN wild-type (WT) protein in the assays studied here. Thus, these rare GRN variants are likely to be polymorphisms rather than pathogenic variants, but we cannot eliminate the possibility that they are risk factors that modify other PGRN functions or the downstream effects of GRN.
Methods
Novel variants were introduced into the pCMVsport6 human GRN WT vector by site-directed mutagenesis using the QuikChangeII Site-Directed Mutagenesis kit (Strategene). Mutations were confirmed by Sanger sequencing.
PGRN secretion and elastase cleavage were measured as previously described ) (see Supplementary data).
Results
Recent deep sequencing of the GRN in clinically diagnosed LOAD families identified several pathogenic mutations and novel variants in GRN (Cruchaga et al., 2012) . These novel variants occur in individuals clinically diagnosed with dementia and do not occur in individuals who are cognitively normal; however, some individuals in these families exhibit clinical dementia without carrying the GRN variant (Table 1) (Cruchaga et al., 2012) . GRN P85A and GRN G515A were detected among unselected African Americans (Exome Variant Server, http://evs.gs.washington.edu/EVS/, Table 1 ). These findings make interpretation of the pathogenicity of these novel variants challenging. PolyPhen predicts that 3 of the 4 novel variants are damaging based on the location of the variant, conservation of the residue, and predicted structural disruption with novel amino acid (Table 1) (Cruchaga et al., 2012) . A protein alignment of these novel variants reveals that, with the exception of GRN P85A, these sites are not highly conserved ( Supplementary Fig. 1 ).
To determine how these variants influence PGRN stability and secretion, vectors containing GRN WT or novel variants were transiently transfected in HEK293T cells, and intracellular and extracellular PGRN protein was measured by immunoblotting. Novel variants produced similar intracellular (Fig. 1B) and extracellular (Fig. 1A) PGRN protein levels compared with PGRN WT, whereas the pathogenic PGRN A9D mutation produced almost no detectable extracellular PGRN (Fig. 1A) . We also observed no difference in the PGRN secretion rate between PGRN WT, a mutation with unclear pathogenicity (P248L), and the novel variants ( Supplementary  Fig. 2 ) (Shankaran et al., 2008; Wang et al., 2010) .
Some pathogenic PGRN mutations, such as C521Y, alter cleavage rather than protein stability and secretion . To measure the influence of these variants on PGRN cleavage, media from cells transiently expressing PGRN WT and novel variants were treated with elastase. Elastase treatment of PGRN WT produced protein fragments at 55, 37, 30, 26, and 19 kDa (Fig. 1C) . Protein fragments at 55 and 37 kDa were absent after 60 minutes of elastase treatment (Fig. 1C) . Novel variants failed to alter GRN cleavage in a similar fashion to the pathogenic PGRN C521Y (Fig. 1C) , which fails to produce the 55-and 37-kDa protein fragments. The novel GRN variants produced protein fragments at 30, 26, and 19 kDa that are more stable than the WT cleavage fragments (Fig. 1C) ; however, the importance of these fragments in PGRN metabolism and function is unknown. 
Discussion
A subset of FTD cases are neuropathologically defined by taunegative, TDP-43, and ubiquitin-positive inclusions in the brain and are associated with mutations in the GRN (Baker et al., 2006; Cruts et al., 2006) . We sought to characterize the pathogenicity of novel GRN variants identified in individuals who were clinically diagnosed with dementia. Novel GRN variants produced PGRN proteins that exhibit protein stability and secretion similar to PGRN WT. The PGRN proteins produced from the novel GRN variants were also cleaved to the same extent as PGRN WT.
The functional role of PGRN and GRN proteins is poorly understood, which makes defining pathogenic variants challenging. Recent evidence suggests the function of PGRN and GRN proteins in the CNS inflammatory response (Yin et al., 2010) , microglial activation (Martens et al., 2012) , synaptic transmission (Tapia et al., 2011) , and neurite outgrowth (Gao et al., 2010) . GRN mutations with unclear pathogenicity (C139R, P248L, R432C) fail to restore neurite outgrowth in GRN-deficient neuronal cultures, whereas a nonpathogenic variant (identified in affected and unaffected individuals) restored neurite outgrowth (Gass et al., 2012) . So, it remains possible that the novel GRN variants described here alter these PGRN functions.
Together, these findings illustrate that these rare variants in GRN are likely to be polymorphisms rather than pathogenic variants. It remains possible that these rare GRN variants represent risk factors for dementia in the presence of additional modifying genes.
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